Trastuzumab Emtansine
CAS: 1018448-65-1
Description:
Trastuzumab emtansine is an antibody-drug conjugate (ADC) used in cancer treatment. It combines trastuzumab, an antibody targeting HER2, with emtansine (DM1), a potent chemotherapy drug. Trastuzumab binds to HER2 on cancer cells, delivering DM1 directly to the tumor, leading to cell death. This therapy is primarily used for HER2-positive breast cancer and HER2-positive metastatic gastric cancer.
Key Features:
- HER2 Targeting: Specifically binds to HER2, a protein overexpressed in certain cancer cells, enabling targeted delivery of DM1.
- Cytotoxic Agent (Emtansine/DM1): DM1 disrupts microtubule function, killing cancer cells.
- Stable Linker: The linker connects trastuzumab to DM1, ensuring targeted delivery to cancer cells.
Applications:
- Cancer Treatment: Targets and destroys HER2-positive cancer cells, especially in HER2-positive breast and metastatic gastric cancer.
- Targeted Therapy: Delivers DM1 directly to tumors, reducing damage to healthy tissue.
- Monoclonal Antibody Therapy: Provides a targeted treatment for patients with HER2-positive cancers, offering an alternative to traditional chemotherapy.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.